ATE173615T1 - Formulierung und verwendung von carotenoiden in der krebsbehandlung - Google Patents

Formulierung und verwendung von carotenoiden in der krebsbehandlung

Info

Publication number
ATE173615T1
ATE173615T1 AT93903070T AT93903070T ATE173615T1 AT E173615 T1 ATE173615 T1 AT E173615T1 AT 93903070 T AT93903070 T AT 93903070T AT 93903070 T AT93903070 T AT 93903070T AT E173615 T1 ATE173615 T1 AT E173615T1
Authority
AT
Austria
Prior art keywords
formulation
lipid
carotenoid
carotenoids
disclosed
Prior art date
Application number
AT93903070T
Other languages
English (en)
Inventor
Kapil Mehta
Roman Perez-Soler
Gabriel Lopez-Berestein
Robert P Lenk
Alan C Hayman
Original Assignee
Univ Texas
Aronex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Aronex Pharmaceuticals Inc filed Critical Univ Texas
Application granted granted Critical
Publication of ATE173615T1 publication Critical patent/ATE173615T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93903070T 1992-01-16 1993-01-13 Formulierung und verwendung von carotenoiden in der krebsbehandlung ATE173615T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82205592A 1992-01-16 1992-01-16

Publications (1)

Publication Number Publication Date
ATE173615T1 true ATE173615T1 (de) 1998-12-15

Family

ID=25235000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93903070T ATE173615T1 (de) 1992-01-16 1993-01-13 Formulierung und verwendung von carotenoiden in der krebsbehandlung

Country Status (8)

Country Link
EP (1) EP0621773B1 (de)
JP (2) JP3691054B2 (de)
AT (1) ATE173615T1 (de)
AU (1) AU3442093A (de)
CA (1) CA2128103C (de)
DE (1) DE69322252T2 (de)
ES (1) ES2128417T3 (de)
WO (1) WO1993013751A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
EP0689426B1 (de) * 1993-03-22 2000-05-17 Betatene Pty. Ltd. Therapeutischer wirkstoff zur behandlung von melanomen
JPH08510995A (ja) * 1993-03-22 1996-11-19 ベータティーン・リミテッド 水分散性治療用化合物
US6020351A (en) * 1995-08-14 2000-02-01 Oxigene, Inc. Carotenoid-nicotinamide-zinc compositions and methods of treatment using same
EP1307220A4 (de) * 2000-03-31 2004-06-16 Aronex Pharmaceuticals Inc Kombination aus interferon alpha und in liposomen eingeschlossener all-trans-retinsäure, deren präparation und verwendung
EP1328262A2 (de) * 2000-10-17 2003-07-23 Board of Regents, The University of Texas System Verfahren zum einfügen von n-(4-hydroxyphenyl)retinamid in liposomen
AU2007270686B2 (en) * 2006-07-07 2011-05-26 Tiltan Pharma Ltd. Anti-cancer therapy comprising an H2-blocker, at least one antiinflammatory agent and a cytotoxic agent
CN107753473A (zh) * 2016-08-18 2018-03-06 杭州高田生物医药有限公司 一种全反式维甲酸注射剂与应用
EP4489744A4 (de) * 2022-03-08 2025-11-05 Mastery Biotech Co Ltd Pharmazeutische zusammensetzung mit retinoinsäure und kohlenhydrat und verwendung davon
EP4670711A1 (de) * 2023-02-24 2025-12-31 Rossi Bergmann, Bartira Liposom, verfahren zur herstellung eines liposoms, intranasale zusammensetzung mit einem liposom, verfahren zur herstellung einer intranasalen zusammensetzung, kit und verwendung der zusammensetzung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
EP0397774A1 (de) * 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulierung und anwendung von retinoiden für behandlung von krebs und anderen krankheiten
CA1340241C (en) * 1988-06-08 1998-12-15 Fountain Pharmaceuticals, Inc. Method for marking solvent dilution microcarriers
DE4005711C1 (de) * 1990-02-23 1991-06-13 A. Nattermann & Cie Gmbh, 5000 Koeln, De

Also Published As

Publication number Publication date
DE69322252T2 (de) 1999-08-12
ES2128417T3 (es) 1999-05-16
EP0621773A1 (de) 1994-11-02
WO1993013751A1 (en) 1993-07-22
CA2128103C (en) 2004-12-28
AU3442093A (en) 1993-08-03
JP3691054B2 (ja) 2005-08-31
JPH07503014A (ja) 1995-03-30
EP0621773B1 (de) 1998-11-25
CA2128103A1 (en) 1993-07-22
DE69322252D1 (de) 1999-01-07
JP2005232182A (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
AU639323B2 (en) Cosmetic composition
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
AU674142B2 (en) Use of cosmetic composition
HU900284D0 (en) Fungicide compositions containing acrylic acid derivatives and process for producing the active substance
EP0301781A3 (en) Cosmetic composition
AU3232789A (en) Anesthetic skin moisturizing composition and method of preparing same
ATE102011T1 (de) Kosmetisches praeparat.
DE3267039D1 (en) Stable s-adenosylmethionine salts, the process for their preparation and therapeutic compositions which contain them as active principle
DE69322252D1 (de) Formulierung und verwendung von carotenoiden in der krebsbehandlung
GR3031691T3 (en) Composition and method for preventing and treating inflammation with immunoglobulin a
DE69535081D1 (de) Verwendung von Prostaglandin A oder dessen Derivaten zur Behandlung von Psoriasis
WO1991004754A3 (en) Illudin analogs as anti-tumor agents
JPS5679616A (en) Whitening cosmetic
SE8204874D0 (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
AU669946B2 (en) Lanolin/lanolin acid ester skin treatment composition
CA2225898A1 (en) Enhancing keratinocyte migration and proliferation
ES8304058A1 (es) Un procedimiento para la preparacion del acido 3,7,11,15-tetrametil-2,4,6,10,14-hexadecapentaenoico.
NO902104L (no) Kosmetisk blanding.
GB8824429D0 (en) U v absorption agents
JPS6483007A (en) Cosmetic
JPS52151149A (en) Cyclopropanecarboxylic acid esters, their preparation, and insecticides and miticides containing same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties